Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atazanavir
Drug ID BADD_D00176
Description Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
Indications and Usage Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
Marketing Status Prescription; Discontinued
ATC Code J05AE08
DrugBank ID DB01072
KEGG ID D07471
MeSH ID D000069446
PubChem ID 148192
TTD Drug ID D07IQS
NDC Product Code 42385-921; 65862-713; 0003-3631; 70518-1365; 70710-1052; 70771-1591; 65862-710; 69097-443; 0003-3622; 69097-444; 65862-711; 11014-0175; 69097-446; 70771-1592; 69238-1137; 16714-860; 31722-654; 42385-922; 42385-920; 0003-3638; 70771-1593; 70710-1051; 0003-3624; 31722-653; 65862-712; 69097-445; 31722-655; 69238-1136; 16714-861; 69238-1138; 70710-1050; 69238-1135; 16714-862; 70518-2832; 0904-6875
Synonyms Atazanavir Sulfate | Reyataz | Atazanavir | 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester | CGP 75176 | CGP75176 | CGP-75176 | CGP 73547 | CGP-73547 | CGP73547 | CGP 75355 | CGP75355 | CGP-75355 | CGP 75136 | CGP75136 | CGP-75136 | BMS-232632-05 | BMS 232632 05 | BMS23263205 | BMS 232632 | 232632, BMS | BMS-232632 | BMS232632
Chemical Information
Molecular Formula C38H52N6O7
CAS Registry Number 198904-31-3
SMILES CC(C)(C)C(C(=O)NC(CC1=CC=CC=C1)C(CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)C(C(C)(C)C)N C(=O)OC)O)NC(=O)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.011--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Yellow skin23.03.03.042; 09.01.01.009; 08.01.03.0460.005512%Not Available
Tubulointerstitial nephritis20.05.02.002--Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.0080.016536%Not Available
Bone marrow toxicity12.03.01.006; 01.03.03.0040.008268%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Temperature intolerance08.01.09.022--Not Available
Dyslipidaemia14.08.04.015--Not Available
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.011024%Not Available
Dysplasia08.03.04.007--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Drug resistance08.06.01.0050.010065%Not Available
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.01.0190.005512%Not Available
Neurological symptom17.02.05.010--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Genital haemorrhage24.07.03.007; 21.10.05.0020.008268%Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages